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Abstract 
The Notch signaling pathway has been implicated in many diseases due to 
deregulation in its role in many cellular processes. One major area of concern is its hand 
in cell proliferation of tumors in cancerous tissues. The extracellular Delta-like Ligand 1 
(DLL1) that binds to Notch receptors has become a focus in recent studies in mice 
models by the Dikov Laboratory and their results suggest that a soluble cluster of a 
multivalent DLL1 may have therapeutic usage to suppress tumor growth. However, these 
DLL1 clusters are heterogeneous collages that are not suitable for in vivo testing or 
therapeutic drug creation. As a result, the Magliery Laboratory is expressing a variety of 
homogeneous DLL proteins. Through optimizing different expression, purification, and 
refolding techniques, numerous refolded DLL1 proteins have already been synthesized. 
These include a long ligand with three Epidermal Growth Factor (EGF) domains, a 
shortened ligand two EGF repeated domains, ligands with and without the N-terminal 
MNNL domain, and ligands with and without a C-terminal cysteine for PEGylation. A 
polyvalent structure of DLL1 ideally would have the potential to prevent tumor 
proliferation and cause apoptosis in cancerous tissues. Currently, we are optimizing the 
crosslinking of these fragments with PEG based linkers to make homogeneous, 
polyvalent constructs. Also, in vitro binding studies of these various proteins to the Notch 
receptor are underway in order to confirm the importance of each domain from our 
findings in the in vivo assays by the Dikov Laboratory.  
Fibrodysplasia Ossificans Progressiva (FOP) is a progressive heterotopic 
endochondral ossification (HEO) that results in bone formation in atypical extra-skeletal 
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locations. A non-lethal heterozygous mutation in the activin receptor IA/activin-like 
kinase-2 (AVCR1/ALK2) was identified as a potential therapeutic target as this mutation 
exists in all cases of FOP. This complex is affiliated with bone morphogenetic protein 
(BMP) signaling receptor complexes, which is known to play a major role in bone and 
cartilage formation among other functions. Since the over-activity of the BMP signaling 
pathway is attributed as the cause to this disease, a possible inhibitor for excessive bone 
growth is a protein called Noggin, which binds and sequesters BMPs. Also a region of 
CV-2 called VWC has been found to bind to a different site on BMPs and sequester 
BMPs. In order to execute a number of different binding studies, optimizing the 
expression and purification of AVCR, BMP2, BMP4, Noggin, and VWC has been the 
initial goals of the Magliery Lab.  
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Chapter 1: Introduction 
1.1 Contributions and Protein Engineering Goals 
 From cloning to expression, I have worked on the initial basic work on both the 
Notch project with Nicholas Emerson Long started by Dr. Brandon Sullivan and the FOP 
project with Dr. Nicholas W. Callahan. In the study of two debilitating diseases, cancer 
and fibrodysplasia ossificans progressiva (FOP), the possibility of further examining 
these diseases through protein engineering is the perspective the Magliery lab has decided 
to take up as possible solutions to these diseases. The Notch signaling pathway has been 
implicated in many diseases due to deregulation in its role in many cellular processes. 
One major area of concern is its hand in cell proliferation of tumors in cancerous tissues. 
The Notch signaling pathway contains a transmembrane receptor that requires 
extracellular substrate binding in order to induce the cascading effect inside the cell. 
Likewise, the same fundamental idea of what causes the crippling FOP disease where 
bone tissue grows and accumulates in askeletal regions. The atypical bone growth from 
FOP is triggered by a protein coded from a mutated ACVR1 gene. This mutation leads to 
the surplus release of internal signaling to stimulate the bone morphogenetic signaling 
pathway for every external binding on the ACVR1 transmembrane protein. Since cancer 
is an increasingly growing phenomenon that amasses much attention from the scientific 
community, rarer diseases such as FOP that share similar fundamental triggers that create 
these health problems can use similar methods of solving the symptomatic onsets. 
Because past research on both of these topics have led to the interest in the characteristics 
 9 
of these proteins that cause these diseases, protein engineering and characterization have 
been main foci in the Magliery lab. 
1.2 Notch Project Background 
Extensive examinations of the Notch signaling pathway have been performed due 
to its vast implications in multiple diseases. The Notch signaling pathway, known to 
control cell-fate specification events and implicated in numerous fundamental regulatory 
processes, is attributed to many developmental defects that lead to a range of known 
diseases (Fortini 2009). The discovery of the Notch signaling pathway in 1916 was first 
observed in X-linked, dominant allele found on the chromosomes of Drosophilia genetic 
mutants, which exhibited missing tissue in irregular notches on the tips of their wing 
blades (Mohr, 1919; Morgan and Bridges, 1916). Then in 1940, Poulson found that a 
complete loss in Notch gene activity caused fatal hyperplasia from cell proliferation of 
the embryonic nervous system. As more research was done on the role of Notch, cell 
proliferation, apoptosis, and the epithelial-mesenchymal transition in eukaryotes are a 
few fundamental processes where any dysregulation or abnormalities in the Notch 
signaling pathway may lead to several diseases (Fortini 2009). For example, T cell acute 
lymphoblastic leukemia (T-ALL), Alagille syndrome, spondylocostal dysostosis, 
Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and 
Leukoencephalopathy (CADASIL) syndrome, and aortic valve disease all deal with the 
abnormal growth or degeneration in the bone or smooth muscle tissues that is contributed 
to some mutation in Notch signaling components (Artavanis-Tsakonas et al., 1999; 
Gridley, 2003). Due to the wide range of other developmentally patterned diseases that 
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are implicated in Notch signaling of vertebrates, Fortini believes that nearly all cells of 
complex animal tissue may potentially have required Notch signaling for differentiation 
at some point (2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1 DLL1 expression in human and mice in normal and tumor tissues (Huang 2011)  
 
A prototypal example of cell proliferation and a driving force for research of the 
Notch signaling pathway is the inhibition of tumor growth in various cancers. Since 
DLL1 is naturally under-expressed in tumors in mice and humans (see Figure 1), 
inducing an overexpression of DLLs in these tumors is the route that the Dikov 
Laboratory chose. A study done by Huang et al. suggests that a soluble multivalent form 
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of Delta-like Ligand 1 (DLL1) may offer an effective strategy for therapeutic treatment to 
overcome T-cell immunosuppression associated with tumors and overall suppress tumor 
growth (2011). However, the DLL1 showed a dose dependency correlation where higher 
density of DLL1 promoted T-cell development and inhibited B-cell development but 
lower density of DLL1 promoted both T-cell and B-cell development (Huang et al., 
2011). This study from the Dikov Laboratory supports the feasible attainment of 
researching the polyvalency of the Notch ligand DLL in suppressing cancer and is the 
collaborative research the Magliery Laboratory intends to build upon. As evident in the 
numerous affected structures of the human body, understanding the Notch receptor 
activation and posttranslational processes that regulate Notch activity may prove 
insightful for comprehending the full dysfunction to cause these diseases.  
The Notch signaling pathway is a well-studied process. The Notch receptor is a 
transmembrane protein that contains an extracellular domain to bind to ligands and an 
intracellular domain that will depart into the cell’s cytoplasm after proteolysis to induce 
transcription in the nucleus (as seen in Figure 1).  
There are two classes of standard Notch ligands: Delta and Serrate/Jagged. The 
Delta ligand was first found in Drosophilia and is a member of the DLS 
(Delta/Serrate/Lag-2) family of ligands (Chillakuri 2012). The homologous Delta-like 
ligand (DLL-1) is found in vertebrates, namely mice and humans. DLL-1 binds to the N-
terminus of the Notch receptor and triggers the proteomic cleavage event that, in return, 
causes a cascade of chemical reactions that end with the promotion of transcription. In 
parallel, Jagged-1, another human homolog to the Jagged found in Drosophilia, is a  
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                        Figure 2 Notch signaling 
pathway (Kageyama 2008) 
ligand that binds to the Notch receptor has already been more deeply studied for its role 
in the Notch signaling pathway. Similarly, studying the DLL1 could lead to greater 
understanding of the immune response tied to the Notch signaling pathway, in particular, 
with DLL1 binding to Notch receptors and its relevance in cancerous tissues. Due to the 
transcriptional control that the Notch signaling pathway exerts, it can easily be seen how 
the deregulation of this system could influence a cell’s protein make-up and cell-fate. 
It is suggested that the deregulation of the Notch signaling pathway is the cause of 
many undesirable cellular processes; however, this research will focus on the binding 
events of the Notch receptors and their influence on cell growth and proliferation in 
cancer. In the Dikov Laboratory, synthesized aggregates of DLL-1 Notch ligands have 
shown potential for the therapeutic treatment of cancer. The collaborators in the Dikov 
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Laboratory have already produced DLL-1 constructs and tested them in mice models in 
the murine Lewis lung carcinoma (LLC) cell lines for their activity. These aggregates 
however are heterogenous mixtures and are therefore unsuited for pharmaceutical usage. 
The Magliery Laboratory is attempting to produce a collection of discrete DLL-1 ligands 
in order to learn more about the Notch signaling pathway’s activation of the Notch 
receptor.  
1.3 FOP Background 
The other disease that is believed could be understood better through studying the 
affected proteins responsible for the disease is FOP. Unlike cancer, FOP is a rarer 
disease, only affecting one in two million individuals (Pignolo 2013). However, there is 
no pattern in predisposition in race, ethnicity, gender, or geographic location for the 
hundreds of individuals diagnosed with classical FOP (Morales-Piga 2010).  
 
Figure 3 Askeletal bone growth typical in FOP (Glaser 2003) 
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FOP is distinguished typically by malformations of the hallux and progressive 
heterotopic endochondral ossification (HEO). FOP is also associated with skeletal 
anomalies such as clinodactyly malformed thumbs, short femoral necks, and proximal 
medial tibial osteochondromas (Kaplan 2009).  HEO is the nonmalignant overgrowth of 
bone through the ossification of cartilage by being replaced by real bone tissue. When 
correctly regulated, this form of bone growth is a normal and essential mechanism in 
embryonic bone development. However, the ankylosed effects from this HEO disorder 
accumulate with every episode of injury, wear, and spontaneous flare-up. These painful 
soft tissue swellings essentially transform ligaments, tendons, aponeuroses, fascia, and 
skeletal muscles into mature heterotopic bone, leading eventually through the process of 
endochondral ossification that replaces skeletal muscles and connective tissues with an 
internal encasement of askeletal bone (Pignolo 2013). The accumulation of this askeletal 
bone leads to permanent immobility of the individual and eventually causes their death 
usually due to complications with thoracic insufficiency syndrome where the thorax can 
no longer support normal respiration and lung function (Campbell 2003). The additive 
disability of FOP usually leaves patients confined to wheelchairs by their third decade of 
life and only gives a median age of survival to be approximately 40 years (Kaplan 2005). 
In efforts to treat this disease, surgery has been tried to remove the excess bone, however 
this results in an even greater return of bone growth (Pignolo 2013). So, current 
management focuses on avoiding injury, controlling pain from flare-ups, and optimizing 
residual function after the episode (Pignolo 2013). In order to obtain a treatment for this 
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disease that does not increase or worsen the HEO flare-ups, research efforts have been 
taken up in order to find the source of this disease. 
In order to understand more about this disease and how it functions, research at 
the genetic level reveals the mutation responsible for FOP. A heterozygous point 
mutation in the gene encoding for 
activin receptor type A (ACVR1) on 
chromosome 2 encodes for a BMP 
type 1 receptor protein called 
activin-like kinase 2 (ALK2) that 
malfunctions and, due to this “gain 
of function” mutation, causes leaky 
expression to the BMP signaling 
pathway (Kaplan 2009). ALK2 (the 
transmembrane protein is also 
commonly referenced as ACVR1) is a receptor targeted by BMP growth factors that are 
responsible for signaling the need for bone growth; however the mutated ACVR1 gene 
destabilizes a glycine-serine (GS) interaction within the activation domain of ALK2, 
leading to an intracellular surplus in signaling for bone growth (Shore 2006; Groppe 
2007). To augment this problem, BMP4 is specifically over-expressed in classically 
diagnosed FOP patients, which activates more signaling in lymphoblastoid cells and 
fibroproliferative cells (Zimmer 2013). The additional bone growth is achieved through 
the excess signal transmitting to the nucleus via phosphorylation of SMAD signaling 
Figure 4 General function of FOP proteins 
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molecules that activates gene transcription (Zimmer 2012). In order to deter overactive 
intracellular signaling, the body already has a controlling mechanism involving the 
extracellular antagonist, Noggin (NOG) (Zimmer 2012). In fact, as a high-affinity 
antagonist of BMP2 and BMP4 that is under-expressed in FOP patients, NOG has been 
considered as a rational treatment for inhibition BMP4 signal transduction pathways 
(Glaser 2003). NOG is a secreted homodimeric protein that inhibits the intracellular 
signal transmission by occluding the binding site on the receptor where BMP would bind 
(Zimmer 2012). This protein seems like a primary candidate to study in order to 
determine an approach to an FOP treatment for its inhibitory sequestering effects on the 
mutated receptor protein. However, studying the BMPs, specifically the ones more 
commonly related to FOP, BMP2 and BMP4, are also targeted for more in depth research 
as they are readily antagonized by wild type NOG (Zimmer 2013). With a similar 
method, a Von Willebrand factor type C domain (VWC) on Crossveinless 2 (CV-2) was 
determined to be responsible for binding to BMP2 and sequestering the molecule so that 
BMP2 is incapable of binding to other receptors (Zhang 2008). As a competitive 
inhibitor, the VWC domain may sequester BMPs, inhibiting their binding to the mutated 
ACVR1 binding site that causes the over stimulated SMAD pathway indicated as the 
cause of FOP. In an effort to analyze these proteins and their interactions that are thought 
to cause FOP, the Magliery lab has decided to produce these proteins for in vitro studies. 
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1.4 Approaches 
1.4.1 Specific to Notch Project 
 In order to create a discrete polyvalent molecule, the first goal was to create 
soluble, folded monomers of the DLL1 ligands. Two approaches were taken to 
accomplish this: attaching a pectate lyase B (pelB) sequence or a Maltose Binding 
Protein (MBP) domain sequence to the desired protein construct and expressing the 
unfolded protein then refolding in vitro using an oxido-shuffling system adapted from 
previous work done on refolding EGF-like domains (Mayhew 1992).  Previously, MBP 
has been successfully used for the soluble overexpression and purification of cysteine-
rich proteins, such as crotamine, and was hoped to have a similar success for DLL1 (Thi 
Vu 2014). In addition to the MBP domain sequence, the sequence for pelB was added to 
the N-terminal end of DLL1 protein constructs in order to pull the fused protein into the 
periplasmic space of the gram-negative bacteria E. coli. This was done in order to 
promote a soluble, folded product by the ions and proteins present in this periplasm. The 
additions of either of these sequences on the DNA level are common techniques in 
genetic protein engineering. Another goal was to determine which domain of DLL1 was 
necessary for binding to the notch receptor. Studies of DLL4 suggest that MNNL and 
EGF domains have specific and essential contact points with the Notch receptor (Luca, 
2015). In order to determine more specifically the binding sites through in vitro binding 
experiments, DLL1 proteins with the additional N-terminal MNNL domain, DSL 
domain, and two or three EGF domains were cloned, expressed with a pelB leader 
sequence, and refolded. With the ultimate goal of producing a discrete polyvalent 
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molecule, a C-terminal cysteine residue was added to the original DSL-EGF-EGF and 
DSL-EGF-EGF-EGF constructs in order to produce a site for maleimide chemistry for 
PEGylation experiments. Because it is currently unknown which domains, and more 
specifically which residues, are responsible for binding the DLL1s to the notch receptor, 
a future goal of the Magliery lab is to study this interaction for all of the expressed and 
soluble monomeric DLL1s via in vitro Surface Plasmon Resonance (SPR) binding 
studies.  
1.4.2 Specific to FOP Project 
 In order to obtain soluble, folded material for binding studies, the first goal of the 
project required experiments to optimize the expression of each of these constructs. Since 
the overall goal of this project is to investigate the bindings between each of these FOP 
related proteins, the Magliery lab would like to collect binding data via SPR and 
understand the structures of these protein complexes via crystallography. Currently, the 
binding and structure between BMP2 and these proteins is known but this remains 
unknown for BMP4. Since BMP4 has been specified as a possible drug target for FOP by 
NOG, studying the interactions between these proteins will be the first step in 
comprehending a drug treatment for FOP.  
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Chapter 2: Materials and Methods 
2.1 Cloning 
2.1.1 General Polymerase Chain Reactions (PCR) Procedure 
 The general PCR reaction requires an initial denaturing of the two original DNA 
strands of the template at 94 °C for 2 min. Then a repeated denaturation at 94 °C for 30 
sec, a specific annealing temperature that worked best for each construct cloned based off 
initial gradient reactions for 30 sec, and an elongation operation at 72 °C for 30 sec. The 
number of cycles for this repeated process was 25 for all PCRs. To finish the reaction, an 
additional extension time of 4 min at 72 °C was spent before bringing the temperature of 
the final product down to 4 °C for storage. The general contents of a PCR reaction 
requires a template, forward primer, reverse primer, dNTPs, polymerase, and the 
respective polymerase’s buffer. These PCR reactions were preformed with Pfu 
polymerase unless otherwise specified with the use of Herculase polymerase.  
2.1.2 General Ligation Reaction Procedure 
 The general ligation reaction required identically digested vectors and inserts. 
Double digests require two specific restriction enzymes and their compatible buffers. For 
these digestions, NEB Cutsmart or 3.1 Buffer was used because of their compatibility 
with NdeI, NcoI, and BamHI. All double digests reacted for 4 hr at 37 °C. Based on the 
concentrations of digested and purified vector and insert, a determined amount of vector 
and insert is determined for each reaction so that the ligation is between equal molar 
ratios of both components. Vector negative and insert negative ligation reactions were 
also done for controls. Each ligation reacted with T4 ligase in T4 ligase buffer at 16 °C 
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overnight. Ligation reactions (1 μl) were transformed into DH10B(DE3) cells and grown 
on antibiotic plates (pHLIC has ampicillin resistance gene) at 37 °C. Colonies picked and 
grown up in small 2YT media cultures and ampicillin overnight at 37 °C in a shaker at 
200 RPM. After hitting the stationary phase of E. coli growth, these cultures were 
purified by DNA miniprep and then analytically digested and sequenced to determine if 
the correct sequence had been successfully ligated together and free from PCR product 
mutations. A glycerol stock of each miniprep was made and stored at -80 °C for back up 
stocks and discarded later if the sequence was determined to be incorrect. 
2.1.3 Cloning MBP and PelB-MBP Notch Constructs 
 PCR were initially set up for creating human and murine constructs with two and 
three EGF repeats. These PCRs were done with Pfu polymerase. The templates and 
primers used for these PCRs can be found in the table below: 
 MBP Hu12 MBP Mu12 
Template Human123  Murine123 
Fwd primer MBP_HuNOTCH_Fwd 
 
ATT ATT ATA CCATGGC  
GAG AAT CTA TAC TTC CAG 
 
MBP_MuNOTCH_Fwd 
 
ATT ATT ATA CCATGGC  
GAG AAT CTC TAT TTC CAG 
 
Rev primer Hu12.rev (H) 
AATAATGGATCCTTACTGGTTACAGAACAACCC 
 
 
Mu12.rev (N) 
 
ATAATGGATCCTTATTGGTTG
CAGAATAAGCC 
Table 1 PCR components for insert products for MBP constructs. Reverse primers remain the same form 
initial construct cloning of huNotch.D12 and muNotch.D12 ordered and used by Dr. Brandon Sullivan 
 
From the pHLIC-MBP plasmid, constructs underwent restriction digestion with 
NcoI and BamHI enzymes and ligated with the purified and identically digested inserts of 
Human DSL-EGF1-EGF2, Human DSL-EGF1-EGF2-EGF3, Murine DSL-EGF1-EGF2, 
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and Murine DSL-EGF1-EGF2-EGF3 that were prepared previously from DLL1 construct 
containing plasmids. 
 
Figure 5 A plasmid map of pHLIC-MBP showing where the restriction enzymes used for cloning, NcoI 
and BamHI cut into the vector. The NdeI site marks where the MBP domain begins. 
 
Figure 6 A plasmid map of pHLIC showing where the restriction enzymes used for cloning, NcoI and 
BamHI cut into the vector to retrieve DLL1 inserts for MBP cloning. This plasmid map contains Hu12 but 
other plasmids containing Hu123, Mu12, and Mu123 were comparable digestion scheme and set up. 
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 In order to clone PelB-MBP, the PCR product was created using the material 
described in Table 2 below. This PCR product was double digested with Nde1 and Nco1 
and ligated with a similarly digested and purified pHLIC-MBP vector. 
 MBP to PelB-MBP plasmid vector 
Template pHLIC-MBP insert 
Fwd primer PelMBP_Fwd: 
ATT ATT ATT CAT ATG AAA 
TAT CTG TTA CCT ACT GCT 
GCT GCG GGA CTA CTT TTA 
TTA GCG GCA CAA CCA GCA 
ATG GCG GCG CAT CAT CAT 
CATCATCACATG 
 
 
Rev primer PelMBP_Rev: 
 
AATAATAATCCATGGCCGAGGTT
GTTG 
 
 
 
Table 2 PCR components for insert for PelB-MBP constructs 
2.1.4 Cloning MNNL Notch Constructs 
 The HuMNNL123 and MuMNNL123 sequences were ordered in kanamycin 
resistant pUC57 plasmid and digested with NdeI and BamHI. The insert containing the 
HuMNNL123 and MuMNNL123 were used for both ligating into a working vector and 
obtaining a smaller PCR product for HuMNNL12 and MuMNNL12 constructs. Digested 
and purified HuMNNL123 and MuMNNL123 were ligated into a purified and similarly 
digested pHLIC vector similar to the one depicted in Figure 8. For the PCR of the two 
smaller constructs, HuMNNL12 and MuMNNL12, the digested HuMNNL123 and 
MuMNNL123 constructs were used as templates. The PCR for the HuMNNL12 required 
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Herculase polymerase while the MuMNNL12 has failed to work with either Herculase or 
Pfu polymerases thus far. The remaining specific contents of each PCR were as follows: 
 HuMNNL12 construct MuMNNL12 construct 
Template HuMNNL123 MuMNNL123 
Fwd 
primer 
HuFwdMNNLpel 
ATTATTCATATGAA 
ATATCTTCTCCCCAC 
 
MuFwdMNNLpel 
   ATTATTATTCATATG 
  AAATACTTGCTACC 
Rev 
primer 
MNNL_Hu12_Rev 
AATAATGGATCCTT 
AGTTGCAGAATAGT 
CCGCCCCAACC 
 
 
Mu12RevMNNL 
   AATAATAATGGATCCTT 
  AATTGCAAAAAAGGCCCCC 
 Table 3 PCR Primers for HuMNNL12 and MuMNNL12 Constructs 
 
Figure 7 A plasmid map of pHLIC showing where the restriction enzymes used for cloning, NdeI and 
BamHI cut into the vector to retrieve DLL1 inserts for MNNL cloning. This particular plasmid contains 
HuMNNL123 but the plasmid containing MuMNNL123 is comparable. After ligation the HuMNNL123 
and the MuMNNL123 are replaced with HuMNNL12 and MuMNNL12 on the plasmid map. 
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2.1.5 Cloning AVCR, VWC, BMP2, BMP4, and Noggin FOP related Constructs  
 Dr. Nicholas W. Callahan’s work on cloning FOP related constructs with a pelB 
sequence prior to the specific human gene sequence for ACVR, VWC, BMP2, BMP4, 
and Noggin provided the basis for using restriction digest and ligation reactions alone to 
achieve different cloning products without the pelB leader sequence. Through digestion 
with NcoI and BamHI in NEB 3.1 Buffer, the desired gene can be isolated from the 
plasmid vector with the pelB leader sequence and ligated into a vector without the pelB 
leader sequence. This allows the expression of this protein that does not initially contain 
the pelB leader sequence and therefore will not be pulled into the periplasmic region of 
the E. coli cells during expression. However, the His tag was left on this construct in 
order to purify it late. To test if the His tag effects the expression of each protein, a 
construct with no tags was constructed. The untagged construct required a PCR to insert a 
restriction site between the His tag sequence and the desired gene sequence. This 
untagged construct was prepared by Dr. Nicholas W. Callahan. 
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Figure 8 A plasmid map of pHLIC showing where the restriction enzymes used for cloning, NcoI and 
BamHI, cut into the vector to retrieve desired gene (in this case ACVR) inserts for each FOP related 
protein. The removed pelB leader sequence is coded for between NdeI and NcoI. For cloning the untagged 
variant, the NCOI restriction site was moved effectively closer to the BamHI site to remove the His-tag 
sequence that exists on this example. 
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2.2 Expression, Lysing, Purification 
2.2.1 Expression and Lysing General Protocol 
All E. coli expressions were completed by transforming the pHLIC plasmid 
containing the desired gene with T7 overexpression into BL21(DE3), Origami, 
C41(DE3), and C43(DE3) cells. The transformed cells are plated on LB Agar media 
plates containing ampicillin and left to incubate at 37 °C overnight. The surviving 
colonies on the plate were successfully transformed by exhibiting the ampicillin 
antibiotic resistance gene coded for in the desired pHLIC plasmid. A single colony is 
picked using flame sterilization and were grown in 2YT media seed cultures of 30 mL 
with .1 g/L ampicillin overnight. These seed cultures were used to inoculate 1 to 2 L of 
fresh 2YT media in 4 L flasks with an additional 0.1 g/L ampicillin. Conditions of the lag 
phase of E. coli growth were optimized with temperature adjustments depending on the 
specific protein constructs, with the employment of baffled or non-baffled flasks, and 
with or without a cold-shock step of incubating at ~4 °C for 30 min to slow cell growth 
before induction. After incubating for 2 hrs in a shaker at 200 RPM, the cultures are 
checked for an OD600 between 0.6 and 1.0 before inducing the culture with 0.5 mM 
IPTG. The cells are then allowed to grow overnight at 16 °C at 120 RPM in the shaker.  
The cell are centrifuged at 6000 RPM for 10 min at 4 °C. After decanting the 
supernatant, the pellets were re-suspended with 25 mL of lysis buffer (50 mM Tris-HCl, 
300 mM NaCl, 10 mM imidazole, pH 8) per liter of culture from which the pellet was 
secured. In addition, 5 mM MgCl2, 0.5 mM CaCl2, 5 µl of DNase and RNase (at 5 
mg/mL each) per liter of culture pelleted, 0.1% Triton X-100, and 25 mg of lysozyme 
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(per liter of culture pelleted). The mixture was nutated for 10 min at 4 °C or allowed to sit 
on ice with occasional agitation for 10 min. The cells were then lysed via glass beads, 
sonication, or Emulsiflex. When lysing with glass beads, 0.1 mm glass beads (~0.5 mL 
per liter of culture pelleted) were vortexed for a total of 10 minutes in the re-suspended 
pellet mixture. When performing the sonication lysing method, the mixture on ice was 
pulsed with an amplitude of 6 for 30 seconds every minute for a total of 6 pulses. When 
utilizing the Emulsiflex instrument, the pellet mixture was kept on ice between three 
cycles through the instrument with a pressure differential between 15,000 and 20,000 psi 
before being flushed out with lysis buffer. Once the lysate obtained a homogenous 
consistency, it was centrifuged for 45 minutes to an hour at 15,000 RPM to 17,000 RPM 
at 4 °C. Depending on the protein expressed, the purification methods were adapted 
appropriately.  
2.2.2 Notch Protein Expression and Purification Protocols: Variants of Hu and Mu 
D12(3)  
Construct Strain Description  MW (kDa) 
35 huNotch.pD123 Human PelB-His6-TEV-DSL-EGF1-EGF2-EGF3 20.9 
36 huNotch.D123 Human His6-TEV-DSL-EGF1-EGF2-EGF3 18.7  
37 huNotch.D12 Human His6-TEV-DSL-EGF1-EGF2 14.3  
38 huNotch.pD12 Human PelB-His6-TEV-DSL-EGF1-EGF2 16.6 
39 muNotch.D123 Murine His6-TEV-DSL-EGF1-EGF2-EGF3 18.7 
40 muNotch.pD123 Murine PelB-His6-TEV-DSL-EGF1-EGF2-EGF3 20.9 
41 muNotch.pD12 Murine PelB-His6-TEV-DSL-EGF1-EGF2 16.6 
42 muNotch.D12 Murine His6-TEV-DSL-EGF1-EGF2 14.3 
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44  MBPhuNotch.D12 Human MBP – TEV – DSL – EGF 1 – EGF 2 57.3 
45 MBPhuNotch.D123 Human MBP – TEV – DSL – EGF 1 – EGF 2 – 
EGF3 
61.7 
46 MBPmuNotch.D12 Murine MBP – TEV – DSL – EGF 1 – EGF 2 57.3 
47 MBPmuNotch.D123 Murine MBP – TEV – DSL – EGF 1 – EGF 2 – 
EGF3 
61.7 
48 pelMBPhuNotch.12 Human pelB-His6 -MBP-TEV-DSL-EGF1-EGF2 59.6 
50 huNotch.D123C His6-TEV-DSL-EGF1-EGF2-EGF3-Cys 
 
19.1  
52 huNotch.D12C 
 
His6-TEV-DSL-EGF1-EGF2-Cys 
 
14.7  
57 huNotch.pMD123 Human pelB-His6 -TEV-MNNL-DSL-EGF1-EGF2-
EGF3 
36.1  
58 muNotch.pMD123 Murine pelB-His6 -TEV-MNNL-DSL-EGF1-EGF2-
EGF3 
34.7  
80 huNotch.pMD12 Human pelB-His6 -TEV-MNNL-DSL-EGF1-EGF2 34.0  
Table 4 DLL1 Construct Variants 
 For both human and murine protein constructs, the respectively gene coded 
plasmid was transformed into C43 (DE3) or Origami (DE3) cells. During lag phase, the 
cultures were incubated at 37 °C in non-baffled flasks. Initially, the culture was then 
cold-shocked for 40 minutes in the cold room at 4 °C but in later modifications to the 
protocol, this step was determined to have little effect on yield and removed. After 
inoculating with IPTG, the expression was allowed to proceed for 6 hours to overnight.  
Several lysing options were used in order to obtain and purify the desired protein. 
Following the glass bead lysis method, the lysate was centrifuged at 17,000 RPM at 4 °C 
for 30 minutes. The supernatant was re-centrifuged in the same way to ensure only 
soluble product was in the sample. This supernatant was mutated with 1 mL Ni-NTA 
50% slurry or Amylose 80% slurry per liter of culture for 30 min in the cold room at 4 
°C. When the supernatant was determined to not contain the desired protein product, 
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larger cultures were grown and lysed following the emulsiflex protocol. The lysate was 
similarly centrifuged but the pellet containing the aggregated desired protein was kept. 
These samples underwent harsh conditions in the unfolding buffer (5 M Guanidine HCl, 
50 mM Tris-HCl, 50 mM NaCl) overnight in a 200 RPM shaker at 37 °C. The sample 
was centrifuged at 17,000 RPM at 4 °C for 30 minutes and the supernatant was then 
refolded through an oxido-shuffling system (100 mM Tris, 0.3 mM cystine, 3 mM 
cysteine, 1 mM EDTA) through dialysis in the cold room at 4 °C in 4 hour increments 
until ~0 M Guanidine HCl was achieved. This method was later shortened and adapted to 
be done with washes (2 M, 1.5 M, 1 M, 0.5 M, 0.25 M, 0.125 M, 0 M unfolding buffer 
series of washes) directly on a Ni-NTA column. Columns were run initially at 4 °C in the 
cold room then modified to be run at 37 °C. Flow through, wash buffer (50 mM Tris-
HCl, 300 mM NaCl, 20 mM imidazole) at 2 mL per liter of culture, and elution buffer (50 
mM Tris-HCl, 300 mM NaCl, 250 - 300 mM imidazole or 1 mM maltose) 3 mL per liter 
of culture were collected to observe on SDS-PAGE gels. 
Collected samples containing the desired protein were then dialyzed into lysis 
buffer. Once in lysis buffer, the sample was TEV cleaved at room temperature with 100 
µl of TEV protease twice for over 6 hours increments in the presence of 5 mM DTT to 
verify identity and obtain the desired untagged protein for assays and analysis. To further 
prepare samples for collaborators, the samples were dialyzed into PBS buffer (8 g NaCl, 
0.2 g KCl, 1.44 g NaHPO4, 0.24 g KH2PO4 in 1 L 18 MΩ-cm water, pH 7.2).  
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2.2.3 FOP Related Protein Expression: Optimization between BL21 (DE3) and C41 
(DE3) cell lines 
Constructs Name Description MW (kDa) 
hNoggin No Tag 23.05 
hVWC1 No Tag 7.33 
hBMP2 No Tag 12.91 
hBMP4 No Tag 13.13 
hACVR1 No Tag 8.75 
His-hNoggin His Tag 25.19 
His-hVWC1 His Tag 9.38 
His-hBMP2 His Tag 15.07 
His-hBMP4 His Tag 15.29 
His-hACVR1 His Tag 10.91 
PelB-His-hNoggin PelB-His Tag 27.37 
PelB-His-hVWC1 PelB-His Tag 11.65 
PelB-His-hBMP2 PelB-His Tag 17.23 
PelB-His-hBMP4 PelB-His Tag 17.45 
PelB-His-hACVR1 PelB-His Tag 13.07 
Table 5 FOP related variants and their molecular weights 
All five FOP related constructs, ACVR1, BMP2, BMP4, VWC, and Noggin, were 
transformed into BL21 cell line and grown in 1 L batches of 2YT media in non-baffled 
flasks as the general protocol dictates without a cold-shock step. After centrifugation, the 
pellets were lysed via sonification after re-suspension in 25 mL of unfolding buffer (6 M 
Guanidine HCl, 20 mM Sodium phosphate, 500 mM NaCl at pH 7.8). The sonicated 
sample was then incubated with 1 mM BME in a 200 RPM shaker at 37 °C for 4 hours. 
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The samples were spun down at 15,000 RPM for 30 minutes at 4 °C. The supernatant 
was then bound with 1 mL Ni-NTA 50% slurry per liter of grown culture and incubated 
overnight at 4 °C on a nutator. Each sample on a column was washed with 10 mL of urea 
wash buffer (8 M urea, 20 mM Sodium Phosphate, 500 mM NaCl, at pH6) and eluted 
with 10 mL of urea elution buffer (8 M urea, 20 mM sodium phosphate, 500 mM NaCl, 
at pH 4). Collected samples were run on an 18% SDS-PAGE gel for analysis.  
2.2.4 FOP Related Protein Expression: Optimization among PelB-His Tagged, His 
Tagged, and Untagged 
 In collaborative efforts with Dr. Nicholas W. Callahan, three variants, PelB-His 
tagged, His-tagged, and untagged, were cloned in pHLIC and ready for transformation. 
Plasmids containing ACVR and VWC were transformed into C41 (DE3) and plasmids 
containing BMP2, BMP4, and Noggin were transformed into BL21 (DE3) as these were 
determined the best cell lines for expression. For controls, BL21 (DE3) and C41 (DE3) 
cells that did not undergo transformation were also prepped the following way for 
expression. As these were a small scale expression experiments, only 1 mL of culture was 
grown up in 2YT media with 0.1 mg/mL of ampicillin and incubated overnight at 37 °C 
in a shaker at 200 RPM. After reaching a saturated state, 100 µl of the saturated sample 
was mixed with 0.1 mg/mL ampicillin in 900 µl of 2YT media and 100 µl of the 
saturated sample was mixed with 100 µM IPTG and 1 mM ampicillin in 900µl of 2YT 
media so that each variant construct had a replicate grown in exactly the same manner 
thus far as a control. With the 100 µM IPTG to induce overexpression, the culture was 
allowed to incubate at 37 °C in a shaker at 200 RPM for 4 hours. These 1 mL cultures 
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were centrifuged at 13,000 RPM at 4 °C for 10 minutes and the supernatant decanted and 
discarded. The pellet, containing the desired protein, was combined with (0.5 µL) 0.1 mm 
glass beads and re-suspended directly with 200 µl of SDS-loading Buffer via vortex for 4 
min for each sample. Samples were heated at 95 °C for 10 min for complete denaturation 
to be ran on an SDS-PAGE gel.  
 
2.3 Conjugation  
2.3.1 Notch C-terminal Cysteine Conjugation Experiments 
 For post-TEV cleaved Notch human constructs following the structure of DSL-
EGF1-EGF2(-EGF3)-Cys, several protocols were followed in order to optimize C-
terminal cysteine PEGylation via maleimide chemistry. Samples were dialyzed into either 
PBS buffer (at pH 7 or pH 8) or lysis buffer (with 10% glycerol, at pH 6) to react with 
PEG solution. Stock PEG solutions were made fresh before each experiment and varied 
in concentration due to calculations based on varying protein concentration 
approximations. The ratio of PEG to targeted protein, the temperature of the reaction, and 
the time allotted for the reaction were controlled variables for each reaction.  
 Due to observing massive over-PEGylation in data priorly collected by Nicholas 
Emerson Long, the first attempt at PEGylation was done at ratios 0.25x, 0.5x, and 1x of 
PEG (20 kDa) to protein in the hopes of a lower PEG concentration would lead to more 
selective cysteine binding. This reaction took place in PBS buffer at pH 7 for 1.5 hours at 
room temperature. The reaction was quenched at 4 °C. 
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 The second attempt at PEGylation was done at room temperature overnight with 
ratios 5x, 10x, and 20x of PEG to protein in both PBS buffer at pH8 and lysis buffer 
(with 10% glycerol at pH6) with 0.1 mM TCEP to free terminal cysteines from dimer 
formation. The reaction was quenched by placing in the fridge at 4 °C.  
 
2.4 Analysis 
2.4.1 Western Blot 
 A 12.5% SDS-PAGE gel was run with the loaded denatured proteins at 180 V for 
one hour. The proteins of the gel was transferred to nitrocellulose paper (HyBond ECL 
from GE Amersham) in a transfer buffer (10% methanol, 25 mM Tris, 192 mM glycine) 
at 200 V for 1 hour and 20 minutes. The membrane was washed five times with PBST 
buffer (0.05% Tween, 8 g NaCl, 0.2 g KCl, 1.44 g NaHPO4, 0.24 g KH2PO4 in 1 L 18 
MΩ-cm water, pH 7.2) and then blocked overnight by incubating the nitrocellulose with 
5% Bovine Serum Albumin (BSA) at 4 ºC. Once the nitrocellulose was blocked for any 
non-specific binding to the membrane, the nitrocellulose was washed with PBST buffer 
three times. The primary antibody (anti-His6-antibody) was diluted in PBS buffer and 
allowed to bind to the specific His6 tag on the desired protein through nutation overnight 
at 4 ºC. The nitrocellulose was washed with PBST buffer five times in 50 mL quantities 
to remove excess primary antibody. After washing, a diaminobenzidine (DAB) solution 
(1 mg/mL diaminobenzidine in 50 mM Tris, pH 7.2) and a hydrogen peroxide (H2O2) 
solution (0.02% H2O2 in PBS buffer) was simultaneously added in equal parts to the 
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washed nitrocellulose in order to develop the membrane. On the developing membrane, a 
brown precipitate formed overtime, indicating the histidine tag on the desired proteins. 
 
2.4.2 Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry 
(MALDI-TOF MS) 
 Protein samples were mixed with an equal sample of the prepped MALDI matrix 
(0.05% TFA, 50% acetonitrile, sinapinic acid). The matrix-protein mixture of each 
sample was loaded in volumes of 1 µL to 1.5 µL onto a clean and dry MALDI plate and 
was then allowed to dry for several hours. Using the Bruker microflex MALDI-TOF MS, 
graduate student Sidharth Mohan operated and collected the data from each sample. 
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Chapter 3: Results and Discussion 
3.1 Notch Project - Cloning, Expression, purification, and refolding of Notch constructs 
3.1.1 Human and Murine (PelB)-His-DSL-EGF1-EGF2-(EGF3) 
 The desired expressed proteins were determined to be insoluble and in the pellet 
after lysing the cells. As seen by the double band in the pellets of the expression, the 
constructs with the PelB leader sequence seemed to not cleave by a signal peptidase in 
the periplasm of the bacteria to cleave off the histidine tag per its normal function. The 
bigger band for theses constructs seems to still have the pelB protein sequence attached to 
the construct, which could lead to messier purification later with two His-tagged 
constructs close in size. Also if the pelB sequence did not successively pull the protein 
into the periplasm to be folded and in the soluble fraction, but instead the desired protein 
aggregates inside the cell during expression, a new strategy would have to be used to 
obtain our samples in the supernatant. It was interesting to see a different protein of a 
comparable size to the notch constructs being expressed but not sticking to the Ni-NTA 
column. We initially doubted this was the desired proteins because they contained the 
His-tag that would bind it to the nickel and should not have ran off the column until the 
elution. To ensure that our interpretations of these gels were correct, a Western Blot was 
run from a new gel containing just the pellets of our lysate.  
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Figure 9 12.5% SDS-PAGE gels comparing expression of human  
and murine constructs with and without pelB leader sequence. 
 
As this was the first time expressing these proteins and due to the mess of the 
pellets on the 12.5% SDS-PAGE gel, a Western Blot was used to detect the presence of 
the N-terminal His tag on the constructs. The anti-His6-antibody bound to the His-tagged 
proteins and was visualized as an insoluble brown color on the nitrocellulose by 3,3′-
Diaminobenzidine (DAB). This is due to the conjugated Horseradish Peroxidase (HRP) 
to the primary antibody that catalyzes chromogenic substrates like DAB to obtain a visual 
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signal. Other bands were present on the gel that suggests that these are co-expressed 
proteins that contain a high number of histidines that were also bound to by the anti-His6-
antibody. 
                                       42     41     40      39     38    36  
 
Figure 10 Wesern Blot confirming via an anti-His6 conjugated  
with HRP that the pellet expression of human and murine  
constructs with and without pelB leader sequence. 
 
Confirming that the desired DLL1 ligands were being expressed in an insoluble 
and unfolded manner, several solution pathways presented themselves. One pathway was 
to clone an MBP tag to the His tagged DLL1 ligands. MBP is a well-behaved and well-
folded protein that when attached to another protein, the MBP tag would hopefully pull 
the proteins into the soluble fraction in the cell. This would mean that the protein would 
be found in the supernatant of the centrifuged lysate and would be in a folded condition 
that is needed for further assays by our collaborators. The other pathway was to take 
these expressions without the pelB sequence in the lysate pellet and re-fold them directly. 
The re-folding experiments were tested with new expression preps of the murine DLL1 
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constructs without the pelB leader sequence due to their better expression concentrations 
as seen on the Western blot (Figure 10). The pellets were re-suspended in a denaturing 
buffer (5 M guanidine hydrochloride, 50 mM Tris, and 50 mM NaCl). The unfolded 
DLL1 ligands were solubilized and were found in the supernatant after centrifugation. 
The supernatant was systematically dialyzed at 4 °C into the oxido-shuffling buffer (5 M, 
2.5 M, and 0 M of the denaturing buffer) containing EDTA, 0.1 M cysteine, and 0.5 M 
cystine. As seen in the 12.5% SDS-PAGE gel (Figure 11), a portion of the desired DLL1 
ligands were soluble in the elutions but much more of the desired protein precipitated in 
the re-folding buffer. 
39    42 
Lysate  Elution   Elution Ppt        Lysate  Elution   Elution Ppt 
                                                     15 µl    5 µl                                15 µl    5 µl 
 
Figure 11 12.5% SDS-PAGE gels comparing soluble elution vs elution precipitate 
 after re-folding experiment for muNotch.D123 and muNotch.D12, respectively. 
For purification, the now soluble protein found in the elution was then TEV 
cleaved and ran on a Ni-NTA column. The TEV cleaved protein lacks the His-tag and 
therefore is found in the flow through fraction of the sample collected from the column 
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and runs farther on SDS-PAGE gels. This common technique for purification was then 
applied to future expressions of proteins.  
                                              
                                              39      39T      42        42T 
 
Figure 12 12.5% SDS-PAGE gels comparing pre-and post-TEV cleavage  
samples of for muNotch.D123 and muNotch.D12, respectively. 
 
 All of the constructs described by the His-TEV-DSL-EGF1-EGF2-(EGF3) were 
re-expressed, re-folded, and TEV-cleaved successfully using this same method (Figure 
12). These sample were prepped for our collaborators with the Dikov laboratory in PBS 
buffer for their assays. 
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        36                   37                  39                 42 
 
Figure 13 Samples prepped for Dikov laboratory collaborators. Concentrations 
Determined from three different amounts loaded on the gel (10 µl, 5 µl, and 2.5  
µl, respectively) 
 
 Though this method worked for folding the DLL1s from the pellets, it was an 
intensive process that is not easily replicated in large batches. If the expressed protein 
was already soluble, the whole re-folding process would be removed and less product 
would be lost due to this step. Attempting to express these four constructs in Origami 
cells, which are known for containing a more oxidized environment that allow the 
cysteine residues to create disulfides more easily and fold proteins like DLL1 with many 
cysteine residues, proved unsuccessful as these DLL1s were expressed in the pellet as 
well. 
 
 
 
 
 
 
Concentration Estimations: 
36 – Hu 1-3         0.4 mg/mL 
37 – Hu 1-2         0.8 mg/mL 
39 – Mu 1-3        0.1 mg/mL 
42 – Mu 1-2        0.4 mg/mL 
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36                  37                 39                 42 
P          E        P        E        P        E         P        E 
 
Figure 14 DLL1 variants expressed in Origami cells 
3.1.2 Human and Murine (PelB)-MBP-His-TEV-DSL-EGF1-EGF2-(EGF3)  
 In order to pull the desired protein into the soluble fraction of the expression in a 
naturally folded way to avoid the re-folding process from the pellet, initially the idea to 
add an MBP tag to the beginning of the sequence would have this desired effect. Yet, the 
initial constructs possessed a PelB leader sequence that could pull the protein to fold in 
the periplasm that has natural proteins that help the creation of disulfide bonds in its 
reducing environment. So this PelB leader sequence was also cloned onto the MBP 
constructs and expression was compared in the C43 (DE3) cell line, in which the original 
constructs that lacked any MBP tag was proven to express best. 
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Human 12     Human 123 
P          FT       W         E      Etev      P       FT        W      E        Etev 
 
Figure 15 1st nickel column and TEV–cleaved product (only depicts human constructs) 
 
 After TEV cleavage, the appearance of just MBP with no DLL1 protein attached 
is seen on the gel in the red box. This hopefully means that our protein was expressed in 
the soluble fraction but our protein could have aggregated or may be the same size as 
another protein in the mess at the bottom of the gel. To clean up the sample, a second Ni-
NTA column was ran with the TEV-cleaved elution sample (Figure 16). However, the 
flow through did not seem to contain much protein the size of the DLL1 proteins and it 
was speculated that during TEV-cleavage, the DLL1s aggregated and precipitated out of 
solution. 
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                                             Human 12        Human 123 
                                          FT    W      E     FT     W      E     
 
Figure 16 2nd nickel column of Human constructs  
 
 Continuing in the efforts towards a soluble DLL1 protein expression, a PelB-MBP 
tag was constructed via PCR and ligated into the pHLIC-MBP vector containing human 
DLL1 with two EGF domains (see protocol 2.1.3). Once the cloning of the PelB-MBP 
construct for the human DLL1 with two EGF domains was sequenced by Genewiz and 
deemed successful, the MBP tag and the PelB-MBP tag were compared for expression in 
C43 cell line. In order to better follow where the DLL1 proteins ended up after TEV-
cleavage, both a Ni-NTA column and Amylose column were run.  
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Figure 17 Ni-NTA column and Amylose column for each sample 
 On the 12.5% SDS-PAGE gel, MBP can be seen to cleave off in both TEV 
cleaved elutions (purple). However, in the amylose columns it is seen that MBP could be 
unintentionally cleaving in an unpredicted location (red) that does not contain the His-tag 
and would otherwise not have been found without the amylose column. There may also 
be unintentional cleaving near the anticipated TEV-cleavage site as shown in the elution 
column for the PelB-MBP Hu12 construct that had not yet been TEV cleaved (blue). 
Regardless, the outcome of where the desired DLL1 proteins are is unpredictable from 
this gel. So in order to determine if the DLL1 proteins were still in the TEV cleaved 
elutions, MALDI mass spectrum was performed on the TEV cleaved fractions. The 
samples ran from the nickel columns were unsuccessful in receiving information from the 
MALDI instrument. 
 
FT    E   tE  FT  E  tE   FT  E  tE  FT  E   tE 
44 Ni 44 Am 48 Am 48 Ni 
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Figure 18 MALDI ran on TEV-cleaved elution samples from Amylose column for pelMBPhuNotch.12 and 
MBPhuNotch.12, respectively. 
 
The peaks on the far right are the bigger MBP proteins while on the left is 
indicative of the smaller DLL1 constructs existing in the TEV-cleaved elutions for both 
the PelB-MBP tagged and the MBP-tagged human DLL1 constructs with two EGF 
Green – 48 Amylose 
Blue and Red – 44 Amylose 
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domains. However, because the DLL1 was not seen on the gel, it appears that the DLL1 
construct has aggregated and is no longer soluble after Tev-cleavage. 
3.1.3 Human and Murine His-TEV-MNNL-DSL-EGF1-EGF2-EGF3 constructs 
 Initially, expressing the truncated DLL1s without the MNNL domains was 
thought to be the easier starting point for expression and binding analysis, but as MNNL 
was thought as a more important domain in the DLL1 constructs for the receptor binding, 
the project shifted to include this domain. As the MNNL domain is the largest domain of 
the DLL1 constructs and had to be ordered separately with three EGF domains. The gene 
constructs had to be digested out of the plasmids that they came in and ligated into 
pHLIC plasmids or used as PCR templates to create the DLL1 constructs with MNNL 
and two EGF domains. Creating the smaller DLL1 constructs were especially difficult 
due to the template size and polymerase ability in the PCR reactions. As the smaller 
MNNL constructs took more time to compose, expressions of the larger MNNL 
constructs were conducted in C43 (DE3) cells. Comparable to the DLL1s lacking the 
MNNL domains, these were still only found to mostly express in the pellet. Even when 
TEV cleaving the flow through of the supernatants, there was no distinguishable size 
change on the gel that would indicate this sized band was the correct protein. 
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Figure 19 Initial MNNL expression in C43 cells 
 
 
Figure 20 TEV-cleaving MNNL DLL1 constructs from 
flow through of the supernatant seen in Figure 18. 
 
 Through re-folding pellets from the subsequent batches of MNNL containing 
DLL1s, a soluble and folded product could be obtained. In the future, this construct along 
with the smaller MNNL containing DLL1s will be used for binding studies and assays by 
our collaborators in Dikov’s lab. 
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3.1.4 Conjugation of Notch C-terminal Cysteine Constructs 
 Constructs with a C-terminal cysteine were constructed via PCR modification of 
the DSL-EGF1-EGF2-(EGF3) constructs for murine and human. The end cysteine 
residue was added in order to be open for maleimide chemistry for conjugation. Initial 
PEGylation experiments were done with the huNotch.D123C construct and a 20 kDa 
PEG molecule but were unsuccessful in showing distinct PEGylation sizes of our desired 
protein. Further optimization was needed for this reaction. One optimization effort was 
towards determining the buffer conditions necessary for PEGylation. Literature reports 
that maleimide chemistry works best at a pH between 5.5 and 7.5. However, our protein 
has been known to precipitate out of solution at lower pHs and high concentrations of salt 
during the conjugation reaction. An attempt at solving this precipitation problem was 
imposed by using a buffer with glycerol that retains a similar pH and salt concentration 
that the storage elution buffer exhibits. Also, since literature reports that maleimide 
chemistry works best at a pH between 5.5 and 7.5 and previous PEGylations done in our 
lab notice more selectivity on the lower end of this range, a conjugation reaction in PBS 
buffer at pH 6 was performed. From the PEGylation reaction, there was a notably smaller 
amount of precipitation in the pH 8 buffer than that in the lower pH buffer. However, it 
seems that there was over-PEGylation in every reaction.    
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Figure 21 Over-PEGylated huNotch.D123C 
 
 In the future, the optimization of this PEGylation reaction will be crucial when 
crosslinking these DLL1s through multi-conjugation molecules. If these conjugations 
with multiple monomers are successful, the creation of a discrete, polyvalent molecule 
could be created and assessed by our collaborators. 
 Figure 22 Future PEG molecules to use for crosslinking, maleimide chemistry 
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3.2 FOP Project 
3.2.1 Cloning and Expression Experiments of FOP Related Constructs 
 In conjunction with Dr. Nicholas W. Callahan, the tags present on the five FOP 
related constructs were modified on their N-terminal end. Beginning with the 
construction of a His-tagged variant, each construct was ligated into a pHLIC vector that 
did not contain a PelB leader sequence.  
AVCR  BMP2  BMP4  NOG   VWC    Vector 
 
Figure 23 Gene construct containing inserts ready for ligation 
Into pHLIC vector. 
 
 These His-tagged variants were tested for expression in BL21 (DE3) cells. In this 
experiment, cells transformed with BMP4 did not grow and BMP4 was not expressed. 
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However, as it was predetermined by a different expression experiment, these proteins all 
express in the pellet. So these constructs underwent lysis in unfolding buffer and then 
purified on a Ni-NTA column, the protein was washed and eluted off in the presence of 8 
M urea at pH 6 and pH 4, respectively. As shown in Figure 24, BMP2 and NOG both 
effectively expressed in BL21 cells and were purified. VWC and ACVR did not express 
in BL21 cells but were expressed by Dr. Nicholas W. Callahan in C43 (DE3) cells later. 
  ACVR                  BMP2                  NOG                  VWC 
       Wash    Elution   Wash    Elution    Wash    Elution   Wash    Elution 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24 Expression of FOP related constructs in BL21 (DE3) cells 
 
3.2.2 PelB-His-tagged vs His-tagged vs Untagged 
When the untagged variants of each FOP related protein were created by 
removing the His tag sequence from each variant via PCR by Dr. Nicholas W. Callahan, 
all the constructs and their variants were tested for which exhibited the best expression. 
With BMP2, BMP4, and NOG transformed into BL21 cells and ACVR and VWC 
transformed into C41 (DE3) cells, a time controlled small scale expression experiment 
was performed.   
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             PelB-His-tagged             His-tagged               Untagged 
              W/O          W/           W/O              W/         W/O          W/ 
 
Figure 25 BMP2 expressed in BL21 cells without and with 100 µM IPTG 
 
 
                           Untagged               His-tagged           PelB-His-tagged 
           W/O          W/           W/O         W/         W/O          W/ 
 
  Figure 26 BMP4 expressed in BL21 cells without and with 100 µM IPTG 
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                        Untagged                His-tagged          PelB-His-tagged 
         W/O          W/           W/O         W/         W/O          W/ 
 
                   Figure 27 NOG expressed in BL21 cells without and with 100 µM IPTG 
 
 
                          Untagged               His-tagged           PelB-His-tagged 
         W/          W/O           W/             W/O         W/          W/O 
 
Figure 28 VWC expressed in C41 cells with and without 100 µM IPTG 
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                               PelB-His-tagged           His-tagged            Untagged 
           W/O          W/           W/O         W/         W/O          W/ 
 
Figure 29 ACVR expressed in C41 (DE3) cells without and with 100 µM IPTG 
 
 
 In the BL21 (DE3) cell line, all three variants of BMP2 expressed well, only the 
untagged and the His-tagged variants of BMP4 expressed, and only the His-tagged NOG 
variant expressed. For best purification methods, the His-tagged variants for these three 
constructs could be expressed well in BL21 (DE3) cells. BMP4 in later experiments 
expressed better while it is tagged. From the C41 (DE3) cell line, VWC only expressed 
with a His-tag while ACVR only expressed with the PelB-His-tag. Expressions of these 
constructs, like those with the notch project, seem to express best by aggregating in the 
cells. Due to this hindrance, re-folding techniques such as those used in the Notch 
project, must be used to retrieve a soluble, folded protein to work with for binding studies 
and crystallography.  
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Conclusions and Future Directions 
 With these additional constructs for both the Notch and FOP projects, a better 
understanding of which constructs can be efficiently expressed in E. coli and purified was 
determined. For the Notch project, the truncated and altered DLL1 constructs will be 
tested for binding affinity to the Notch 1 receptor through SPR. Additionally, these 
constructs will be used in in vitro assays done by the collaboration with the Dikov 
laboratory. For the FOP project, the human constructs that were determined to express 
the best in E. coli will continue to be used as the best method for expression for future 
binding and characterization studies. The Magliery laboratory hopes to continue research 
in both of these projects to acquire more insight into the proteins associated with both the 
Notch signaling pathway in cancer and Fibrodysplasia Ossificans Progressiva, 
respectively. 
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